2024第三届生物偶联药全球创新峰会9月无锡召开！近百位国际生命科学大咖齐聚无锡，探索偶联药的无限可能！

由药明合联WuXi XDC和佰傲谷BioValley共同主办的2024第三届生物偶联药全球创新峰会（Global XDC 2024），将于9月10-12日在无锡重磅回归。大会涵盖2个主论坛+4个分论坛，预计参会企业300+家，参会专家100+位，参会观众1000+人。大会以“探索偶联药的无限可能”为主题，将聚焦于新靶点发现与验证、ADC和新型偶联药物创新技术、载荷-连接子新技术，以及CMC挑战和商业化策略等内容，探索前沿技术进步、分享国际优秀生物科技公司的创新经验、引领ADC和XDC的新未来！

本届峰会邀请了众多生物偶联药领域的国际专家与会，共同探讨创新合作，碰撞思想，助力生物偶联药行业蓬勃发展。

1.国际嘉宾阵容来袭，聆听偶联药的世界声音

2.精选热门议题一览，探索偶联药的无限可能

Keynote Speech

• Rina-S-the missing link(er) 

• Protein homeostasis by dual-precision targeted protein degradation and stabilization 

• A novel dual-payload ADC platform to overcome payload resistance and maximize therapeutic promise of ADCs 

• MYTX-011: a cMET-targeting ADC engineered for anti-tumor activity against a broader spectrum of cMET expression

• NTX1105: development of a best-in-class ADC targeting Nectin-4 

• Collaborating within the global life science ecosystem to advance breakthrough science

论坛一：Next generation ADCs: Novel targets, payloads, payload-linkers, and conjugation technologies

• Next generation ADCs: novel targets, payloads, linkers and conjugation technologies

• Nexatecan™: OHPAS-able Topo1 inhibitor for ADC

• Introduction to PINOT-ADC platform: novel Top1 inhibitor payload, tandem cleavable and super-hydrophilic linker,   and dual payload system

• Versatile drug bundle-based ADC platform: achieving site-specific conjugation, DAR of 8 or 12, and dual payloads

• CS5001, a potential best-in-class ROR1 ADC

• Discovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload

• Polysorbates in biopharmaceuticals-approaches to mitigate risk

论坛二：Bioconjugates development beyond ADCs

• RDC-the exploration of new drug modality in unmet clinical need

• Intra-cellular mutant epitopes-novel targets for ADC and bispecific antibodies?

• GBB’s AI-enabled ecosystem elevating biological drug development

• Developing radiopharmaceuticals targeting CLDN 18.2 with nanobodies

• Fully human common light chain technology for novel ADCs

论坛三：Innovative bioconjugate discovery: from target selection to PreClinical Candidate (PCC)

• Harnessing AbClick Pro® for AT-211: leading CLDN 18.2 ADCs with superior therapeutic index

• An overview on the new topoisomerases inhibitors technologies

• Next generation ADCs:novel targets, payloads, linkers and conjugation technologies

• Challenges and solutions for clinical PK bioanalysis of antibody drug conjugates (ADCs)

论坛四：CMC challenges and commercialization strategies

• CMC scale-up challenges and COGs for site specific ADCs

• Innovative bioassays: translate clinical effects into a rigorous system of XDC product assessment

• The integrated analytical platform enables accelerated CMC development of XDCs

• QbD considerations for ADC process

• How WuXiBio’s Microbial Platform facilitates rapid and cost-effective ADC development and manufacturing

• Non-clinical strategies for ADC drugs

3.欢迎更多XDC研发企业加入我们

主办单位：药明合联WuXi XDC、佰傲谷BioValley

大会时间：2024年9月10-12日（周二/周三/周四）

大会地点：中国·无锡君来洲际酒店

参会报名：扫码下方二维码报名

【标准通票：200元/人】

联系我们：定制参展/商务合作请联系：Stephen Sun 15966587556（微信同号）

参会报名/媒体合作请联系：Abby Jiang 18217659261（微信同号）

4.特别感谢以下单位的支持